EIF2S3 Antibody

What is EIF2S3 and what role does it play in cellular processes?

EIF2S3 (eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa) is a critical component of the protein translation machinery. It encodes the γ subunit of the heterotrimeric translation initiation factor 2 (eIF2) complex that plays an essential role in the initiation of protein synthesis. The eIF2 complex, consisting of distinct α, β, and γ subunits, interacts with GTP and initiator methionyl-tRNA to form a ternary complex that binds the 40S ribosomal subunit. This complex then scans mRNA to identify the AUG start codon for protein synthesis initiation . Beyond its fundamental role in translation, EIF2S3 is also involved in the regulation of the integrated stress response (ISR), a cellular pathway that responds to various stress conditions by modulating protein synthesis rates .

What are the clinical implications of EIF2S3 dysfunction?

Pathogenic variants in the EIF2S3 gene have been linked to several clinical disorders with varying severity. Most notably, mutations can cause X-linked intellectual disability syndrome MEHMO (mental deficiency, epilepsy, hypogenitalism, microcephaly, and obesity) . The clinical presentation ranges from severe neurological phenotypes with intellectual disability and extreme microcephaly to milder manifestations involving hypopituitarism with glucose dysregulation and minimal neurological involvement. The severity of symptoms appears to correlate with the degree to which EIF2S3 function is compromised, though the precise mechanisms governing this relationship remain incompletely understood .

What types of EIF2S3 antibodies are available for research purposes?

Several types of EIF2S3 antibodies are available for research applications, including:

• Polyclonal antibodies (such as 11162-1-AP) derived from rabbit hosts

• Monoclonal antibodies with various isotypes (e.g., IgG2a,k)

• Antibodies with different detection systems including unconjugated, biotin-conjugated, and fluorophore-conjugated (e.g., MaxLight 550) versions

• Antibodies raised against different epitopes of the EIF2S3 protein

• Species-specific antibodies with reactivity to human, mouse, rat, or rabbit EIF2S3

These diverse options allow researchers to select the most appropriate antibody based on their experimental design, detection method, and target species.

What are the recommended applications for EIF2S3 antibodies in research?

EIF2S3 antibodies have been validated for multiple experimental applications, with specific recommendations for each technique:

These applications have been successfully demonstrated in various sample types, including mouse thymus tissue, HeLa cells, human lung cancer tissue, and human tonsillitis tissue . It is strongly recommended to optimize antibody concentration for each specific application and sample type to obtain optimal results.

What are the optimal conditions for using EIF2S3 antibodies in Western blotting?

For Western blot applications using EIF2S3 antibodies, the following methodological considerations are important:

The recommended dilution range is typically 1:500-1:2000, though this should be optimized for each experimental system . EIF2S3 protein has a calculated molecular weight of 52 kDa, which aligns with its observed molecular weight on SDS-PAGE gels . For antigen retrieval in fixed tissues or cells, TE buffer at pH 9.0 is recommended, though citrate buffer at pH 6.0 can be used as an alternative .

When developing the methodology, researchers should consider:

• Including appropriate positive controls (e.g., mouse thymus tissue or HeLa cell lysate)

• Using detection systems compatible with rabbit IgG (for polyclonal antibodies)

• Optimizing blocking conditions to minimize background

• Considering the storage buffer components (PBS with 0.02% sodium azide and 50% glycerol, pH 7.3) when planning wash steps and incubation conditions

How can I optimize immunohistochemistry protocols using EIF2S3 antibodies?

For successful immunohistochemistry experiments with EIF2S3 antibodies, consider the following optimization approaches:

The recommended dilution range for IHC applications is 1:50-1:500 . Antigen retrieval is crucial for optimal staining, with TE buffer at pH 9.0 being the suggested method. Alternatively, citrate buffer at pH 6.0 can be used if needed .

Human lung cancer tissue and human tonsillitis tissue have been successfully used as positive controls for IHC applications . The antibody has demonstrated specific staining patterns that align with the expected cellular localization of EIF2S3.

For protocol optimization, consider:

• Testing multiple antibody dilutions within the recommended range

• Comparing different antigen retrieval methods

• Optimizing incubation times and temperatures

• Using appropriate detection systems compatible with rabbit-derived antibodies

• Including proper controls to validate specificity and minimize background staining

How can EIF2S3 antibodies be used to investigate disease mechanisms in translational research?

EIF2S3 antibodies serve as valuable tools for exploring disease mechanisms, particularly in conditions associated with translational dysregulation. Pathogenic variants in EIF2S3 have been linked to MEHMO syndrome and other disorders involving intellectual disability and metabolic abnormalities .

When investigating disease mechanisms:

• Western blot analysis can be used to detect mutant eIF2γ protein expression levels in patient-derived cells, as demonstrated in lymphoblastoid cells from affected individuals

• Immunohistochemistry can reveal altered tissue distribution patterns in affected tissues

• Immunoprecipitation combined with mass spectrometry can identify aberrant protein interactions in disease states

• Comparative studies between wild-type and mutant EIF2S3 can provide insights into functional consequences of pathogenic variants

By analyzing how disease-associated mutations impact EIF2S3 expression, localization, or function, researchers can gain deeper insights into pathophysiological mechanisms and potential therapeutic targets.

What approaches can be used to validate EIF2S3 antibody specificity for critical research applications?

Validating antibody specificity is essential for ensuring reliable experimental results, particularly in studies investigating EIF2S3 function and pathology. Several complementary approaches are recommended:

• Genetic validation: Use cells with EIF2S3 knockdown or knockout as negative controls to confirm signal specificity

• Peptide competition assays: Pre-incubate the antibody with excess immunizing peptide before application to verify that specific binding is blocked

• Multiple antibody validation: Compare results using different antibodies targeting distinct epitopes of EIF2S3

• Cross-species reactivity testing: Confirm that reactivity patterns match evolutionary conservation expectations

• Recombinant protein controls: Use purified recombinant EIF2S3 protein as a positive control

• Western blot analysis: Verify that the detected protein band corresponds to the expected molecular weight (52 kDa)

Implementing multiple validation strategies provides greater confidence in antibody specificity and experimental results.

How can EIF2S3 antibodies be employed in studies of stress response pathways?

EIF2S3, as part of the eIF2 complex, plays a critical role in the integrated stress response (ISR), making its antibodies valuable tools for studying cellular stress mechanisms . Advanced applications include:

• Phosphorylation studies: Combine EIF2S3 antibodies with phospho-specific antibodies to analyze stress-induced modifications of the eIF2 complex

• Stress-response time course experiments: Monitor changes in EIF2S3 localization, expression, or interactions following exposure to various stressors

• Co-immunoprecipitation studies: Identify stress-specific interaction partners of EIF2S3 under different conditions

• Proximity ligation assays: Detect and quantify protein-protein interactions involving EIF2S3 in situ

• Chromatin immunoprecipitation: Investigate potential roles of EIF2S3 in stress-induced transcriptional regulation

These approaches can provide mechanistic insights into how cellular stress impacts translation initiation and the broader stress response network.

What are common issues encountered when using EIF2S3 antibodies and how can they be addressed?

Researchers working with EIF2S3 antibodies may encounter several technical challenges that can be resolved through methodological adjustments:

• Weak or absent signal:

  • Increase antibody concentration within the recommended range (e.g., 1:500 instead of 1:2000 for WB)

  • Optimize antigen retrieval methods, comparing TE buffer (pH 9.0) and citrate buffer (pH 6.0)

  • Extend primary antibody incubation time or adjust temperature

  • Use more sensitive detection systems

• High background or non-specific binding:

  • Decrease antibody concentration

  • Extend blocking time or try alternative blocking reagents

  • Increase wash duration and frequency

  • Pre-absorb the antibody with non-relevant tissues

• Multiple bands in Western blot:

  • Optimize sample preparation to reduce protein degradation

  • Adjust running conditions to improve separation

  • Verify sample integrity and protein extraction protocol

  • Consider potential post-translational modifications or isoforms

• Inconsistent results between experiments:

  • Standardize protocols including incubation times and temperatures

  • Prepare fresh working solutions for each experiment

  • Aliquot antibody to avoid freeze-thaw cycles

  • Store antibody according to manufacturer recommendations (-20°C, stable for one year)

How should researchers approach designing multiplex experiments that include EIF2S3 antibodies?

Designing effective multiplex experiments with EIF2S3 antibodies requires careful planning to ensure compatibility between reagents and optimal detection of all targets:

• Antibody selection considerations:

  • Choose antibodies raised in different host species to avoid cross-reactivity

  • For same-species antibodies, use directly conjugated primary antibodies

  • Verify that all selected antibodies work under compatible conditions

• Spectral separation for immunofluorescence:

  • Select fluorophores with minimal spectral overlap

  • Include appropriate controls to assess and correct for bleed-through

  • Consider sequential rather than simultaneous detection if cross-reactivity occurs

• Protocol harmonization:

  • Identify buffer systems and fixation methods compatible with all antibodies

  • Optimize antigen retrieval conditions that work for all targets

  • Test antibodies individually before combining in multiplex assays

• Technical considerations:

  • For immunohistochemistry, consider chromogenic vs. fluorescent detection based on experiment goals

  • For flow cytometry, carefully titrate each antibody in the multiplex panel

  • For Western blotting, consider molecular weight differences between targets

Successful multiplex experiments provide richer datasets while conserving valuable samples and reducing experimental variability.

How might advanced imaging techniques enhance EIF2S3 antibody applications in research?

Emerging imaging technologies offer exciting opportunities to extend the utility of EIF2S3 antibodies beyond traditional applications:

• Super-resolution microscopy techniques (STORM, PALM, STED) can reveal previously undetectable details of EIF2S3 subcellular localization and dynamics within translation initiation complexes, providing insights into spatial organization that standard immunofluorescence cannot achieve.

• Live-cell imaging using minimally disruptive antibody-based probes (such as nanobodies or Fab fragments) can track EIF2S3 dynamics during stress responses or disease processes in real-time, offering temporal resolution critical for understanding dynamic cellular processes.

• Expansion microscopy combined with EIF2S3 immunolabeling can physically enlarge specimens to reveal nanoscale details of translation machinery organization using standard confocal microscopy equipment.

• Correlative light and electron microscopy (CLEM) approaches can connect EIF2S3 immunofluorescence localization with ultrastructural contexts at near-molecular resolution, providing unprecedented insights into the structural relationships within the translation initiation complex.

• Intravital imaging techniques could potentially track EIF2S3 dynamics in living organisms under physiological or pathological conditions, though such applications would require significant methodological development.

What are emerging applications for EIF2S3 antibodies in understanding neurodevelopmental disorders?

Given the association between EIF2S3 mutations and neurodevelopmental disorders, antibodies targeting this protein have significant potential for advancing understanding of pathological mechanisms:

The link between pathogenic EIF2S3 variants and conditions such as X-linked intellectual disability, particularly as part of MEHMO syndrome, highlights the importance of translation regulation in neurodevelopment . EIF2S3 antibodies can be instrumental in investigating:

• Patient-derived cellular models: Antibodies can help characterize EIF2S3 expression, localization, and function in iPSC-derived neurons from patients with EIF2S3 mutations, comparing these to control cells to identify disease-specific alterations.

• Brain organoid studies: Immunohistochemistry using EIF2S3 antibodies can reveal developmental abnormalities in three-dimensional brain organoid models of neurodevelopmental disorders.

• Stress response dysregulation: By studying how mutant EIF2S3 affects the integrated stress response in neurons, researchers may identify converging pathways that connect translation dysregulation to neurodevelopmental pathology.

• Therapeutic development: EIF2S3 antibodies can serve as tools to assess the efficacy of experimental therapies aimed at correcting translation defects in preclinical models.

• Biomarker identification: Studies correlating EIF2S3 expression patterns with clinical features may help identify diagnostic or prognostic biomarkers for related neurodevelopmental disorders.